LU86289A1 - Formulation a liberation prolongee contenant des alcaloides de l'ergot de seigle - Google Patents

Formulation a liberation prolongee contenant des alcaloides de l'ergot de seigle Download PDF

Info

Publication number: LU86289A1
Authority: LU; Luxembourg
Prior art keywords: formulation according; dihydroergotamine; fat; dergocrine; substance
Prior art date: 1985-02-05

Application number

LU86289A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-02-05

Filing date

1986-02-04

Publication date

1986-09-02

1985-02-05 Priority claimed from GB858502889A external-priority patent/GB8502889D0/en

1985-07-12 Priority claimed from GB858517604A external-priority patent/GB8517604D0/en

1986-02-04 Application filed by Sandoz Sa filed Critical Sandoz Sa

1986-09-02 Publication of LU86289A1 publication Critical patent/LU86289A1/fr

Links

239000000203 mixture Substances 0.000 title claims description 49
238000009472 formulation Methods 0.000 title claims description 34
229960003133 ergot alkaloid Drugs 0.000 title claims description 11
239000012730 sustained-release form Substances 0.000 title claims description 11
238000013268 sustained release Methods 0.000 title claims description 10
229960004704 dihydroergotamine Drugs 0.000 claims description 25
239000000126 substance Substances 0.000 claims description 22
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 21
230000008961 swelling Effects 0.000 claims description 14
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical group NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims description 9
229930013930 alkaloid Natural products 0.000 claims description 9
229940074979 cetyl palmitate Drugs 0.000 claims description 9
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 9
SBFXHXZNBNFPHV-PXXBSISHSA-N epicriptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)[C@H](C)CC)C(C)C)=C3C2=CNC3=C1 SBFXHXZNBNFPHV-PXXBSISHSA-N 0.000 claims description 7
150000003797 alkaloid derivatives Chemical class 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
239000008187 granular material Substances 0.000 claims description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
150000004665 fatty acids Chemical class 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
229930015720 peptide alkaloid Natural products 0.000 claims description 4
-1 fatty acid ester Chemical class 0.000 claims description 3
239000000416 hydrocolloid Substances 0.000 claims description 3
125000000129 anionic group Chemical group 0.000 claims description 2
125000005456 glyceride group Chemical group 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
229920001206 natural gum Polymers 0.000 claims 1
239000002775 capsule Substances 0.000 description 21
239000004615 ingredient Substances 0.000 description 20
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
238000011282 treatment Methods 0.000 description 13
239000003925 fat Substances 0.000 description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
239000008101 lactose Substances 0.000 description 11
150000001875 compounds Chemical class 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 8
235000013305 food Nutrition 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
239000002253 acid Substances 0.000 description 7
239000000377 silicon dioxide Substances 0.000 description 7
230000000694 effects Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
239000012458 free base Substances 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
208000001407 Vascular Headaches Diseases 0.000 description 3
229950001817 alpha-ergocryptine Drugs 0.000 description 3
239000000470 constituent Substances 0.000 description 3
229940069063 dihydro-beta-ergocryptine Drugs 0.000 description 3
SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 3
229960004290 dihydroergocornine Drugs 0.000 description 3
LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 3
229960004318 dihydroergocristine Drugs 0.000 description 3
ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
229960000807 dihydroergotamine mesylate Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
230000002746 orthostatic effect Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
206010000599 Acromegaly Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000004604 Blowing Agent Substances 0.000 description 1
235000013912 Ceratonia siliqua Nutrition 0.000 description 1
240000008886 Ceratonia siliqua Species 0.000 description 1
241001440269 Cutina Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000001287 Galactorrhea Diseases 0.000 description 1
206010017600 Galactorrhoea Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000569 Gum karaya Polymers 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
229920003095 Methocel™ K15M Polymers 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
241000428199 Mustelinae Species 0.000 description 1
206010036832 Prolactinoma Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000934878 Sterculia Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000036626 alertness Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
229960002032 dihydroergocryptine Drugs 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
229940040520 ergoloid mesylates Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
125000005908 glyceryl ester group Chemical group 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
235000010494 karaya gum Nutrition 0.000 description 1
239000000231 karaya gum Substances 0.000 description 1
229940039371 karaya gum Drugs 0.000 description 1
230000006651 lactation Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
229940106045 methylcellulose (1500 cps) Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000002942 palmitic acid derivatives Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
230000009758 senescence Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LU86289A 1985-02-05 1986-02-04 Formulation a liberation prolongee contenant des alcaloides de l'ergot de seigle LU86289A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8502889		1985-02-05
GB858502889A GB8502889D0 (en)	1985-02-05	1985-02-05	Co-dergocrine compositions
GB858517604A GB8517604D0 (en)	1985-07-12	1985-07-12	Dihydroergotamine compositions
GB8517604		1985-07-12

Publications (1)

Publication Number	Publication Date
LU86289A1 true LU86289A1 (fr)	1986-09-02

Family

ID=26288767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU86289A LU86289A1 (fr)	1985-02-05	1986-02-04	Formulation a liberation prolongee contenant des alcaloides de l'ergot de seigle

Country Status (24)

Country	Link
JP (1)	JPS61183225A (da)
KR (1)	KR920010388B1 (da)
AU (1)	AU597570B2 (da)
BE (1)	BE904152A (da)
CA (1)	CA1263087A (da)
CH (1)	CH667592A5 (da)
CY (1)	CY1604A (da)
DE (1)	DE3602577A1 (da)
DK (1)	DK167138B1 (da)
ES (1)	ES8800040A1 (da)
FR (1)	FR2576787B1 (da)
GB (1)	GB2170407B (da)
GR (1)	GR860310B (da)
HK (1)	HK57191A (da)
HU (1)	HU195729B (da)
IE (1)	IE59293B1 (da)
IT (1)	IT1191255B (da)
LU (1)	LU86289A1 (da)
NL (1)	NL8600161A (da)
NZ (1)	NZ215020A (da)
PH (1)	PH23384A (da)
PT (1)	PT81954B (da)
SE (1)	SE8600496L (da)
SG (1)	SG56191G (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2610827B1 (fr) *	1987-02-18	1991-09-13	Pf Medicament	Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
SI8710406B (sl) *	1987-03-11	1998-08-31	Lek	Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo
US7771746B2 (en)	1999-12-03	2010-08-10	Polichem Sa	Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
EP1512403A1 (en) *	1999-12-03	2005-03-09	Polichem S.A.	Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US6696491B2 (en)	2000-05-12	2004-02-24	Meracol Corporation Limited	Treating irritable bowel syndrome or disease
NZ504526A (en) *	2000-05-12	2003-05-30	Meracol Corp Ltd	Treating herpes simplex symptoms using a mixture of cetyl myristate and cetyl palmitate
CA2408541C (en) *	2000-05-12	2009-07-28	Meracol Corporation Limited	Treating eczema and/or psoriasis
US20030153620A1 (en)	2000-05-12	2003-08-14	Meakin Timothy David	Treating eczema and/or psoriasis
WO2003026640A1 (en) *	2001-09-28	2003-04-03	Meracol Corporation Limited	Treating food allergies and/or food intolerances
CN111297815B (zh) *	2020-04-29	2022-04-15	宝利化（南京）制药有限公司	一种甲磺酸二氢麦角碱缓释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3147187A (en) *	1962-09-10	1964-09-01	Don Hall Lab	Sustained release pharmaceutical
CH630257A5 (en) *	1975-03-17	1982-06-15	Hoffmann La Roche	Sustained release formulation
DE3124983A1 (de) *	1981-06-25	1983-01-20	Meditest Inst Fuer Medizinisch	Arzneiformen zur oralen verabreichung
CH649300A5 (de) *	1981-08-07	1985-05-15	Sandoz Ag	Ergopeptinderivate, ihre herstellung und verwendung.
US4369172A (en) *	1981-12-18	1983-01-18	Forest Laboratories Inc.	Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3303616A1 (de) *	1982-02-12	1983-08-25	Sandoz-Patent-GmbH, 7850 Lörrach	Mutterkornalkaloide, verfahren zu deren herstellung sowie diese verbindungen enthaltende pharmazeutische zubereitungen
US4421736A (en) *	1982-05-20	1983-12-20	Merrel Dow Pharmaceuticals Inc.	Sustained release diethylpropion compositions
JPS604120A (ja) *	1983-06-22	1985-01-10	Shionogi & Co Ltd	作用持続型ピナシジル製剤
GB2154874B (en) *	1984-02-29	1987-11-04	Sandoz Ltd	Bromoscriptine compositions
GB8413795D0 (en) *	1984-05-30	1984-07-04	Sandoz Ltd	Organic compounds

1986
- 1986-01-24 HU HU86361A patent/HU195729B/hu not_active IP Right Cessation
- 1986-01-24 NL NL8600161A patent/NL8600161A/nl not_active Application Discontinuation
- 1986-01-27 CH CH296/86A patent/CH667592A5/de not_active IP Right Cessation
- 1986-01-29 DE DE19863602577 patent/DE3602577A1/de not_active Ceased
- 1986-01-31 FR FR868601477A patent/FR2576787B1/fr not_active Expired - Lifetime
- 1986-02-03 BE BE1/011431A patent/BE904152A/fr not_active IP Right Cessation
- 1986-02-03 GR GR860310A patent/GR860310B/el unknown
- 1986-02-03 AU AU52942/86A patent/AU597570B2/en not_active Ceased
- 1986-02-03 IE IE29186A patent/IE59293B1/en not_active IP Right Cessation
- 1986-02-03 GB GB08602602A patent/GB2170407B/en not_active Expired
- 1986-02-03 CA CA000501011A patent/CA1263087A/en not_active Expired
- 1986-02-03 DK DK052086A patent/DK167138B1/da not_active IP Right Cessation
- 1986-02-03 PT PT81954A patent/PT81954B/pt not_active IP Right Cessation
- 1986-02-03 NZ NZ215020A patent/NZ215020A/xx unknown
- 1986-02-03 KR KR1019860000698A patent/KR920010388B1/ko not_active Expired
- 1986-02-04 PH PH33379A patent/PH23384A/en unknown
- 1986-02-04 ES ES551635A patent/ES8800040A1/es not_active Expired
- 1986-02-04 LU LU86289A patent/LU86289A1/fr unknown
- 1986-02-04 JP JP61023666A patent/JPS61183225A/ja active Pending
- 1986-02-04 SE SE8600496A patent/SE8600496L/ not_active Application Discontinuation
- 1986-02-05 IT IT47620/86A patent/IT1191255B/it active
1991
- 1991-07-16 SG SG561/91A patent/SG56191G/en unknown
- 1991-07-25 HK HK571/91A patent/HK57191A/xx unknown
1992
- 1992-04-03 CY CY1604A patent/CY1604A/en unknown

Also Published As

Publication number	Publication date
GB2170407A (en)	1986-08-06
FR2576787A1 (fr)	1986-08-08
CA1263087A (en)	1989-11-21
PT81954A (en)	1986-03-01
DK167138B1 (da)	1993-09-06
IT8647620A0 (it)	1986-02-05
JPS61183225A (ja)	1986-08-15
DK52086D0 (da)	1986-02-03
GR860310B (en)	1986-05-27
IE860291L (en)	1986-08-05
ES551635A0 (es)	1987-10-16
NL8600161A (nl)	1986-09-01
SE8600496L (sv)	1986-08-06
IT1191255B (it)	1988-02-24
HU195729B (en)	1988-07-28
BE904152A (fr)	1986-08-04
PH23384A (en)	1989-07-26
IE59293B1 (en)	1994-02-09
PT81954B (pt)	1988-07-01
ES8800040A1 (es)	1987-10-16
KR860006265A (ko)	1986-09-09
HK57191A (en)	1991-08-02
AU5294286A (en)	1986-08-14
DK52086A (da)	1986-08-06
KR920010388B1 (ko)	1992-11-27
HUT41984A (en)	1987-06-29
SG56191G (en)	1991-08-23
FR2576787B1 (fr)	1990-01-12
DE3602577A1 (de)	1986-08-28
NZ215020A (en)	1989-07-27
CH667592A5 (de)	1988-10-31
GB2170407B (en)	1988-10-26
AU597570B2 (en)	1990-06-07
SE8600496D0 (sv)	1986-02-04
GB8602602D0 (en)	1986-03-12
CY1604A (en)	1992-04-03

Publication	Publication Date	Title
EP1108424B2 (fr)	2013-09-04	Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale
JP2001500883A (ja)	2001-01-23	低脂質値のためのシブトラミン類似物の使用
CH679011A5 (da)	1991-12-13
JPH11512115A (ja)	1999-10-19	経口投与用製剤組成物
TW200831134A (en)	2008-08-01	Phenylalkyl carbamate compositions
LU86289A1 (fr)	1986-09-02	Formulation a liberation prolongee contenant des alcaloides de l'ergot de seigle
FR2600253A1 (fr)	1987-12-24	Nouvelles compositions pharmaceutiques a base de ketotifene
JPH085787B2 (ja)	1996-01-24	痴呆及び脳血管障害予防・治療剤並びに血小板凝集抑制剤
GB2154874A (en)	1985-09-18	Bromocriptine compositions
BE1007024A5 (fr)	1995-02-21	Compositions a activite agoniste des recepteurs analogues a 5ht1, selective.
BE1010972A6 (fr)	1999-03-02	Composition pharmaceutique antituberculeuse et procede destine a produire ladite composition.
US5069911A (en)	1991-12-03	Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
FR2604902A1 (fr)	1988-04-15	Compositions pharmaceutiques a liberation prolongee
EP1358159B1 (fr)	2009-07-22	Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
CN114746092A (zh)	2022-07-12	D-苯丙胺化合物、组合物、以及制备和使用它们的方法
JP4945043B2 (ja)	2012-06-06	モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤
EP0966276B1 (fr)	2003-12-10	Utilisation d'agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants
FR2861299A1 (fr)	2005-04-29	Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
LU85331A1 (fr)	1984-11-28	Nouvelle association medicamenteuse pour le traitement de l'hypertension
FR2589732A1 (fr)	1987-05-15	Nouvelle formulation a liberation prolongee a base de pindolol
CH684161A5 (fr)	1994-07-29	Compositions pharmaceutiques contenant un composé à activité agoniste sélective aux récepteurs analogues à la 5-HT(1) dérivés de l'indole.
EP1465607A1 (fr)	2004-10-13	Compositions pharmaceutiques a liberation modifiee
FR2560047A1 (fr)	1985-08-30	Compositions de bromocriptine
LU86290A1 (fr)	1986-09-02	Compositions pharmaceutiques a base de 3-aminopropoxyindoles
EP0412877A1 (fr)	1991-02-13	Nouvelle forme galénique orale améliorant la biodisponibilité